| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Experimental | 26 | 2023 | 195 | 11.700 |
Why?
|
| Endothelin-1 | 38 | 2022 | 122 | 9.210 |
Why?
|
| Stroke | 55 | 2023 | 2163 | 8.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 36 | 2020 | 1085 | 6.220 |
Why?
|
| Brain Ischemia | 33 | 2023 | 665 | 5.610 |
Why?
|
| Cognitive Dysfunction | 14 | 2022 | 176 | 5.510 |
Why?
|
| Infarction, Middle Cerebral Artery | 22 | 2023 | 105 | 5.380 |
Why?
|
| Rats, Wistar | 63 | 2022 | 371 | 5.090 |
Why?
|
| Cerebrovascular Circulation | 18 | 2022 | 296 | 4.850 |
Why?
|
| Neovascularization, Pathologic | 12 | 2019 | 183 | 4.250 |
Why?
|
| Rats | 89 | 2023 | 5300 | 4.110 |
Why?
|
| Hyperglycemia | 11 | 2023 | 158 | 3.690 |
Why?
|
| Brain | 30 | 2022 | 2176 | 3.670 |
Why?
|
| Sulfonamides | 16 | 2022 | 141 | 3.640 |
Why?
|
| Microglia | 8 | 2022 | 143 | 3.600 |
Why?
|
| Animals | 141 | 2023 | 20881 | 3.510 |
Why?
|
| Receptor, Endothelin A | 19 | 2022 | 35 | 3.230 |
Why?
|
| Endothelial Cells | 17 | 2022 | 384 | 3.190 |
Why?
|
| Endothelins | 10 | 2022 | 57 | 3.180 |
Why?
|
| Receptor, Endothelin B | 20 | 2022 | 34 | 3.020 |
Why?
|
| Cerebral Hemorrhage | 12 | 2018 | 198 | 2.890 |
Why?
|
| Diabetes Mellitus | 11 | 2022 | 694 | 2.830 |
Why?
|
| Dementia, Vascular | 5 | 2022 | 22 | 2.710 |
Why?
|
| Recovery of Function | 13 | 2019 | 506 | 2.600 |
Why?
|
| Diabetes Complications | 7 | 2020 | 249 | 2.490 |
Why?
|
| Reperfusion Injury | 11 | 2017 | 320 | 2.440 |
Why?
|
| Diabetic Angiopathies | 10 | 2017 | 203 | 2.440 |
Why?
|
| Middle Cerebral Artery | 10 | 2016 | 57 | 2.410 |
Why?
|
| Muscle, Smooth, Vascular | 9 | 2018 | 317 | 2.410 |
Why?
|
| Neuroprotective Agents | 16 | 2021 | 317 | 2.390 |
Why?
|
| Disease Models, Animal | 38 | 2023 | 2550 | 2.360 |
Why?
|
| Endothelin A Receptor Antagonists | 12 | 2018 | 22 | 2.300 |
Why?
|
| Cognition | 8 | 2021 | 513 | 2.230 |
Why?
|
| Microvessels | 7 | 2022 | 43 | 2.220 |
Why?
|
| Neovascularization, Physiologic | 8 | 2014 | 164 | 2.190 |
Why?
|
| Receptor, Angiotensin, Type 2 | 7 | 2022 | 31 | 2.170 |
Why?
|
| Matrix Metalloproteinase 3 | 5 | 2022 | 22 | 2.160 |
Why?
|
| Linagliptin | 4 | 2016 | 6 | 2.150 |
Why?
|
| Mesenteric Arteries | 12 | 2015 | 29 | 2.140 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2018 | 296 | 2.050 |
Why?
|
| Endothelin B Receptor Antagonists | 8 | 2018 | 11 | 2.030 |
Why?
|
| Endothelin Receptor Antagonists | 7 | 2018 | 17 | 2.010 |
Why?
|
| Endothelium, Vascular | 16 | 2020 | 371 | 1.980 |
Why?
|
| Receptors, Endothelin | 10 | 2022 | 30 | 1.960 |
Why?
|
| Pyrrolidines | 15 | 2012 | 45 | 1.880 |
Why?
|
| Hypoglycemic Agents | 7 | 2016 | 362 | 1.830 |
Why?
|
| Matrix Metalloproteinases | 13 | 2010 | 223 | 1.820 |
Why?
|
| Cerebrovascular Disorders | 5 | 2016 | 182 | 1.800 |
Why?
|
| Blood Glucose | 12 | 2020 | 631 | 1.770 |
Why?
|
| Male | 106 | 2022 | 37321 | 1.720 |
Why?
|
| Vascular Remodeling | 5 | 2016 | 34 | 1.710 |
Why?
|
| Thiophenes | 10 | 2022 | 76 | 1.610 |
Why?
|
| Peroxynitrous Acid | 5 | 2017 | 55 | 1.590 |
Why?
|
| Hypertension | 20 | 2020 | 1535 | 1.550 |
Why?
|
| Cognition Disorders | 3 | 2019 | 342 | 1.490 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 10 | 2019 | 95 | 1.460 |
Why?
|
| Hippocampus | 7 | 2019 | 471 | 1.430 |
Why?
|
| Renin-Angiotensin System | 4 | 2019 | 79 | 1.430 |
Why?
|
| Vasodilation | 13 | 2017 | 85 | 1.420 |
Why?
|
| Benzimidazoles | 13 | 2018 | 128 | 1.400 |
Why?
|
| Diet, High-Fat | 9 | 2020 | 81 | 1.390 |
Why?
|
| Behavior, Animal | 7 | 2019 | 470 | 1.280 |
Why?
|
| Inflammasomes | 3 | 2019 | 39 | 1.260 |
Why?
|
| Sex Characteristics | 3 | 2019 | 295 | 1.260 |
Why?
|
| Cerebral Arteries | 6 | 2016 | 50 | 1.220 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2019 | 22 | 1.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2017 | 219 | 1.210 |
Why?
|
| Vasoconstriction | 10 | 2014 | 81 | 1.150 |
Why?
|
| Fibrinolytic Agents | 8 | 2018 | 377 | 1.110 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 34 | 1.090 |
Why?
|
| Oxidative Stress | 11 | 2017 | 718 | 1.060 |
Why?
|
| Tetrazoles | 12 | 2018 | 160 | 0.970 |
Why?
|
| Minocycline | 7 | 2017 | 61 | 0.950 |
Why?
|
| Vascular Resistance | 4 | 2013 | 179 | 0.950 |
Why?
|
| Up-Regulation | 8 | 2016 | 682 | 0.930 |
Why?
|
| Metformin | 3 | 2014 | 63 | 0.910 |
Why?
|
| Cerebrum | 4 | 2022 | 20 | 0.890 |
Why?
|
| Aspartic Acid Endopeptidases | 5 | 2006 | 47 | 0.880 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 20 | 0.840 |
Why?
|
| Brain-Derived Neurotrophic Factor | 4 | 2018 | 124 | 0.820 |
Why?
|
| Bacteroidaceae Infections | 1 | 2022 | 15 | 0.820 |
Why?
|
| Humans | 61 | 2022 | 68618 | 0.810 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2018 | 1745 | 0.800 |
Why?
|
| White Matter | 3 | 2022 | 174 | 0.800 |
Why?
|
| Brain Edema | 6 | 2015 | 50 | 0.800 |
Why?
|
| Porphyromonas gingivalis | 1 | 2022 | 33 | 0.800 |
Why?
|
| Thrombolytic Therapy | 6 | 2015 | 233 | 0.770 |
Why?
|
| Vasodilator Agents | 6 | 2017 | 138 | 0.760 |
Why?
|
| Glucose | 4 | 2018 | 307 | 0.750 |
Why?
|
| Metalloendopeptidases | 7 | 2006 | 67 | 0.750 |
Why?
|
| Imidazoles | 3 | 2022 | 175 | 0.750 |
Why?
|
| Lipopolysaccharides | 3 | 2020 | 455 | 0.720 |
Why?
|
| Inflammation | 5 | 2020 | 1030 | 0.710 |
Why?
|
| NADPH Oxidases | 3 | 2016 | 80 | 0.700 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 16 | 0.670 |
Why?
|
| Vasoconstrictor Agents | 5 | 2010 | 107 | 0.670 |
Why?
|
| Basilar Artery | 5 | 2013 | 38 | 0.660 |
Why?
|
| Palmitates | 2 | 2018 | 20 | 0.660 |
Why?
|
| Metalloporphyrins | 3 | 2013 | 25 | 0.650 |
Why?
|
| Signal Transduction | 12 | 2020 | 2689 | 0.650 |
Why?
|
| Furans | 1 | 2019 | 27 | 0.650 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 4 | 2016 | 59 | 0.640 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 126 | 0.640 |
Why?
|
| Neurons | 3 | 2019 | 881 | 0.630 |
Why?
|
| Female | 32 | 2022 | 38074 | 0.630 |
Why?
|
| Nerve Degeneration | 2 | 2018 | 134 | 0.620 |
Why?
|
| Th17 Cells | 1 | 2019 | 116 | 0.620 |
Why?
|
| Neurocognitive Disorders | 1 | 2018 | 23 | 0.620 |
Why?
|
| Antioxidants | 6 | 2014 | 304 | 0.610 |
Why?
|
| Mice | 17 | 2021 | 8474 | 0.600 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 37 | 0.600 |
Why?
|
| Cell Line | 6 | 2021 | 1752 | 0.590 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 114 | 0.590 |
Why?
|
| Cerebral Cortex | 3 | 2014 | 415 | 0.560 |
Why?
|
| Tyrosine | 5 | 2017 | 196 | 0.550 |
Why?
|
| Matrix Metalloproteinase 9 | 7 | 2013 | 160 | 0.550 |
Why?
|
| Coronary Artery Bypass | 4 | 2004 | 218 | 0.550 |
Why?
|
| Actin Cytoskeleton | 1 | 2016 | 37 | 0.540 |
Why?
|
| Hypoxia | 2 | 2016 | 169 | 0.540 |
Why?
|
| Rats, Inbred Strains | 7 | 2014 | 532 | 0.540 |
Why?
|
| Education, Graduate | 1 | 2016 | 30 | 0.530 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 248 | 0.520 |
Why?
|
| Streptozocin | 3 | 2020 | 34 | 0.520 |
Why?
|
| Matrix Metalloproteinase 2 | 6 | 2010 | 145 | 0.500 |
Why?
|
| Blood Vessels | 3 | 2017 | 102 | 0.490 |
Why?
|
| Aorta | 4 | 2017 | 316 | 0.490 |
Why?
|
| Obesity | 8 | 2016 | 1076 | 0.480 |
Why?
|
| Oxadiazoles | 1 | 2014 | 7 | 0.480 |
Why?
|
| Education, Medical | 1 | 2016 | 147 | 0.480 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 149 | 0.470 |
Why?
|
| Intracranial Hemorrhages | 3 | 2013 | 80 | 0.460 |
Why?
|
| Receptors, Angiotensin | 3 | 2021 | 59 | 0.460 |
Why?
|
| Cell Line, Transformed | 3 | 2018 | 100 | 0.450 |
Why?
|
| Blood-Brain Barrier | 5 | 2022 | 99 | 0.450 |
Why?
|
| Gene Expression Regulation | 6 | 2017 | 1293 | 0.440 |
Why?
|
| Saphenous Vein | 2 | 2004 | 61 | 0.440 |
Why?
|
| Pericytes | 3 | 2022 | 81 | 0.440 |
Why?
|
| Curcumin | 1 | 2013 | 23 | 0.430 |
Why?
|
| Cells, Cultured | 9 | 2019 | 2673 | 0.430 |
Why?
|
| Acetylcholine | 6 | 2013 | 64 | 0.430 |
Why?
|
| Time Factors | 15 | 2019 | 4655 | 0.420 |
Why?
|
| Muscle Contraction | 3 | 2013 | 210 | 0.420 |
Why?
|
| Insulin | 4 | 2013 | 619 | 0.410 |
Why?
|
| Reactive Oxygen Species | 6 | 2019 | 499 | 0.410 |
Why?
|
| Collagen | 4 | 2010 | 636 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2019 | 331 | 0.400 |
Why?
|
| Deferoxamine | 2 | 2022 | 45 | 0.390 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 144 | 0.370 |
Why?
|
| Cardiovascular Diseases | 4 | 2012 | 940 | 0.360 |
Why?
|
| Neurovascular Coupling | 2 | 2020 | 9 | 0.340 |
Why?
|
| Biphenyl Compounds | 12 | 2018 | 184 | 0.340 |
Why?
|
| Ischemic Preconditioning | 3 | 2014 | 31 | 0.330 |
Why?
|
| Cell Hypoxia | 3 | 2020 | 92 | 0.310 |
Why?
|
| Dietary Fats | 1 | 2008 | 103 | 0.310 |
Why?
|
| Stress, Physiological | 2 | 2014 | 215 | 0.310 |
Why?
|
| Brain Infarction | 2 | 2007 | 54 | 0.310 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2005 | 282 | 0.300 |
Why?
|
| Dyslipidemias | 1 | 2008 | 98 | 0.300 |
Why?
|
| Mammary Arteries | 2 | 2004 | 18 | 0.300 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 82 | 0.300 |
Why?
|
| Blood Pressure | 10 | 2018 | 1451 | 0.290 |
Why?
|
| Acute Disease | 6 | 2017 | 658 | 0.290 |
Why?
|
| Apoptosis | 5 | 2018 | 1641 | 0.290 |
Why?
|
| Sex Factors | 3 | 2020 | 1266 | 0.290 |
Why?
|
| Carrier Proteins | 3 | 2014 | 597 | 0.280 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2017 | 80 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor B | 2 | 2018 | 8 | 0.280 |
Why?
|
| In Vitro Techniques | 7 | 2014 | 765 | 0.280 |
Why?
|
| Phosphorylation | 8 | 2016 | 1200 | 0.280 |
Why?
|
| Motor Activity | 3 | 2019 | 621 | 0.270 |
Why?
|
| Rats, Inbred SHR | 7 | 2020 | 95 | 0.270 |
Why?
|
| Muscle Development | 2 | 2018 | 31 | 0.270 |
Why?
|
| Radial Artery | 1 | 2006 | 43 | 0.270 |
Why?
|
| Endothelin-Converting Enzymes | 5 | 2006 | 15 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type I | 3 | 2017 | 35 | 0.260 |
Why?
|
| Thromboembolism | 2 | 2018 | 91 | 0.260 |
Why?
|
| Telencephalon | 1 | 2005 | 6 | 0.260 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 565 | 0.260 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 202 | 0.250 |
Why?
|
| Ethidium | 1 | 2004 | 4 | 0.250 |
Why?
|
| Amyloid beta-Peptides | 3 | 2022 | 191 | 0.250 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 226 | 0.240 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2004 | 20 | 0.240 |
Why?
|
| Thioredoxins | 2 | 2014 | 26 | 0.240 |
Why?
|
| Vasculitis | 1 | 2004 | 33 | 0.240 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 59 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 66 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2018 | 155 | 0.230 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 73 | 0.230 |
Why?
|
| ErbB Receptors | 1 | 2005 | 239 | 0.230 |
Why?
|
| Hyperlipidemias | 2 | 2016 | 90 | 0.230 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2015 | 25 | 0.230 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2001 | 50 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 9 | 2017 | 2791 | 0.220 |
Why?
|
| Down-Regulation | 3 | 2017 | 447 | 0.220 |
Why?
|
| Nitric Oxide | 5 | 2015 | 382 | 0.220 |
Why?
|
| Actins | 2 | 2016 | 249 | 0.220 |
Why?
|
| Mice, Knockout | 6 | 2019 | 1692 | 0.220 |
Why?
|
| Hemin | 1 | 2022 | 10 | 0.220 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2001 | 250 | 0.210 |
Why?
|
| Hyperemia | 2 | 2013 | 14 | 0.210 |
Why?
|
| Acetylglucosamine | 2 | 2016 | 46 | 0.210 |
Why?
|
| Interleukin-10 | 2 | 2017 | 144 | 0.210 |
Why?
|
| Neuronal Plasticity | 2 | 2017 | 274 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 370 | 0.210 |
Why?
|
| Cell Nucleus | 1 | 2003 | 305 | 0.210 |
Why?
|
| Base Composition | 1 | 2022 | 22 | 0.210 |
Why?
|
| Treatment Outcome | 7 | 2017 | 7029 | 0.210 |
Why?
|
| Coronary Vessels | 1 | 2004 | 313 | 0.200 |
Why?
|
| Retina | 2 | 2014 | 252 | 0.200 |
Why?
|
| Tibial Arteries | 1 | 2002 | 6 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 85 | 0.200 |
Why?
|
| Nootropic Agents | 2 | 2018 | 18 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 234 | 0.200 |
Why?
|
| Matrix Metalloproteinase 13 | 3 | 2011 | 24 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 208 | 0.190 |
Why?
|
| Sulfones | 2 | 2019 | 45 | 0.190 |
Why?
|
| Aorta, Thoracic | 3 | 2009 | 211 | 0.190 |
Why?
|
| Phylogeny | 1 | 2022 | 197 | 0.190 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2022 | 134 | 0.190 |
Why?
|
| Penis | 3 | 2010 | 25 | 0.190 |
Why?
|
| Phenylalanine | 1 | 2000 | 22 | 0.190 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 434 | 0.180 |
Why?
|
| Rats, Mutant Strains | 2 | 2013 | 14 | 0.180 |
Why?
|
| Blotting, Western | 6 | 2013 | 954 | 0.180 |
Why?
|
| Exercise Therapy | 2 | 2012 | 183 | 0.180 |
Why?
|
| Georgia | 2 | 2016 | 161 | 0.180 |
Why?
|
| Tunica Media | 2 | 2010 | 33 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 364 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.180 |
Why?
|
| Gray Matter | 1 | 2020 | 57 | 0.180 |
Why?
|
| Myocardium | 3 | 2001 | 1204 | 0.180 |
Why?
|
| Extracellular Space | 1 | 2000 | 121 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 1851 | 0.170 |
Why?
|
| Culture Media | 1 | 2020 | 155 | 0.170 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2019 | 2 | 0.170 |
Why?
|
| Cell Polarity | 1 | 2019 | 49 | 0.170 |
Why?
|
| RNA, Messenger | 7 | 2011 | 1664 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2017 | 102 | 0.170 |
Why?
|
| NADPH Oxidase 2 | 2 | 2016 | 16 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 53 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 710 | 0.170 |
Why?
|
| Ion Channels | 1 | 2019 | 72 | 0.170 |
Why?
|
| Indenes | 1 | 2019 | 6 | 0.170 |
Why?
|
| Ephrin-B2 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2019 | 10 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 3 | 2016 | 18 | 0.160 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2019 | 20 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 167 | 0.160 |
Why?
|
| Interleukin-17 | 1 | 2019 | 62 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 34 | 0.160 |
Why?
|
| Antihypertensive Agents | 4 | 2018 | 498 | 0.160 |
Why?
|
| Cell Movement | 4 | 2019 | 630 | 0.160 |
Why?
|
| Intestines | 1 | 2019 | 114 | 0.160 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 35 | 0.160 |
Why?
|
| Insulin Resistance | 2 | 2018 | 241 | 0.160 |
Why?
|
| Viper Venoms | 2 | 2008 | 8 | 0.160 |
Why?
|
| Cell Division | 1 | 2019 | 541 | 0.150 |
Why?
|
| Isoenzymes | 3 | 2006 | 308 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.150 |
Why?
|
| Necrosis | 1 | 2018 | 239 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 397 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 529 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 212 | 0.140 |
Why?
|
| NF-kappa B | 3 | 2013 | 432 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2014 | 2083 | 0.140 |
Why?
|
| NADPH Oxidase 4 | 1 | 2016 | 17 | 0.140 |
Why?
|
| Maze Learning | 1 | 2017 | 138 | 0.140 |
Why?
|
| Superoxides | 2 | 2013 | 70 | 0.140 |
Why?
|
| Locomotion | 2 | 2018 | 135 | 0.140 |
Why?
|
| Homeostasis | 1 | 2018 | 291 | 0.140 |
Why?
|
| Phenotype | 2 | 2017 | 947 | 0.140 |
Why?
|
| Arterioles | 2 | 2013 | 40 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2016 | 18 | 0.140 |
Why?
|
| Nerve Growth Factors | 2 | 2017 | 75 | 0.140 |
Why?
|
| Exploratory Behavior | 1 | 2017 | 79 | 0.140 |
Why?
|
| Random Allocation | 4 | 2018 | 442 | 0.140 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2016 | 10 | 0.140 |
Why?
|
| Oxygen | 4 | 2017 | 386 | 0.130 |
Why?
|
| Microcirculation | 3 | 2013 | 77 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2016 | 15 | 0.130 |
Why?
|
| Comorbidity | 2 | 2020 | 1426 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 201 | 0.130 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 172 | 0.130 |
Why?
|
| Disease Progression | 3 | 2017 | 1038 | 0.130 |
Why?
|
| Mentors | 1 | 2016 | 81 | 0.130 |
Why?
|
| Risk Factors | 3 | 2018 | 5731 | 0.130 |
Why?
|
| Ribonucleosides | 1 | 2015 | 5 | 0.130 |
Why?
|
| Fear | 1 | 2017 | 239 | 0.130 |
Why?
|
| Body Weight | 3 | 2018 | 554 | 0.130 |
Why?
|
| Enzyme Activators | 1 | 2015 | 14 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 901 | 0.130 |
Why?
|
| Cell Proliferation | 3 | 2014 | 1174 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 56 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 196 | 0.130 |
Why?
|
| Sutures | 1 | 2015 | 32 | 0.120 |
Why?
|
| Ischemic Postconditioning | 1 | 2014 | 2 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 250 | 0.120 |
Why?
|
| Heart Failure | 2 | 2000 | 1180 | 0.120 |
Why?
|
| CHO Cells | 2 | 2006 | 161 | 0.120 |
Why?
|
| Cricetinae | 2 | 2006 | 262 | 0.120 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2014 | 41 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2006 | 659 | 0.120 |
Why?
|
| Placenta | 1 | 2015 | 101 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 34 | 0.120 |
Why?
|
| Desoxycorticosterone | 3 | 2009 | 41 | 0.120 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2014 | 10 | 0.120 |
Why?
|
| Cerebral Infarction | 3 | 2010 | 103 | 0.120 |
Why?
|
| Protein Subunits | 1 | 2014 | 99 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 507 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 2 | 2006 | 200 | 0.120 |
Why?
|
| Cell Communication | 1 | 2015 | 116 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1174 | 0.120 |
Why?
|
| Metabolome | 1 | 2014 | 15 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2014 | 85 | 0.120 |
Why?
|
| Uterine Artery | 1 | 2013 | 5 | 0.120 |
Why?
|
| Neutrophils | 2 | 2005 | 204 | 0.110 |
Why?
|
| Caspase Inhibitors | 1 | 2013 | 36 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2013 | 328 | 0.110 |
Why?
|
| Catechin | 1 | 2013 | 26 | 0.110 |
Why?
|
| Embolism | 1 | 2013 | 45 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 160 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 223 | 0.110 |
Why?
|
| Piperazines | 1 | 2015 | 206 | 0.110 |
Why?
|
| Pulmonary Fibrosis | 1 | 2015 | 157 | 0.110 |
Why?
|
| Eye Diseases | 1 | 2013 | 38 | 0.110 |
Why?
|
| Penile Erection | 2 | 2010 | 18 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 376 | 0.110 |
Why?
|
| Kidney | 3 | 2005 | 945 | 0.110 |
Why?
|
| Microscopy, Video | 1 | 2013 | 27 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 786 | 0.110 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2013 | 17 | 0.110 |
Why?
|
| Nitroprusside | 2 | 2013 | 42 | 0.110 |
Why?
|
| Isoprostanes | 1 | 2012 | 3 | 0.110 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 163 | 0.110 |
Why?
|
| Research | 1 | 2014 | 214 | 0.110 |
Why?
|
| Arachidonic Acids | 1 | 2013 | 97 | 0.110 |
Why?
|
| Endocannabinoids | 1 | 2013 | 32 | 0.110 |
Why?
|
| Androgens | 1 | 2013 | 41 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 160 | 0.110 |
Why?
|
| Collagen Type I | 2 | 2011 | 175 | 0.110 |
Why?
|
| Capillary Permeability | 2 | 2009 | 69 | 0.110 |
Why?
|
| Edema | 1 | 2013 | 66 | 0.110 |
Why?
|
| Triglycerides | 1 | 2013 | 184 | 0.110 |
Why?
|
| Retinal Vessels | 1 | 2013 | 74 | 0.110 |
Why?
|
| Testosterone | 1 | 2013 | 96 | 0.100 |
Why?
|
| Aging | 1 | 2018 | 911 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2006 | 498 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 286 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 299 | 0.100 |
Why?
|
| Cholesterol | 1 | 2013 | 331 | 0.100 |
Why?
|
| Cell Death | 3 | 2020 | 329 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2008 | 147 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 640 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 137 | 0.100 |
Why?
|
| Spironolactone | 1 | 2011 | 13 | 0.100 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 133 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 468 | 0.090 |
Why?
|
| Vagina | 1 | 2011 | 88 | 0.090 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 191 | 0.090 |
Why?
|
| Reperfusion | 2 | 2007 | 78 | 0.090 |
Why?
|
| Astrocytes | 1 | 2013 | 270 | 0.090 |
Why?
|
| Hemoglobins | 3 | 2007 | 120 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1738 | 0.090 |
Why?
|
| Pia Mater | 1 | 2009 | 1 | 0.090 |
Why?
|
| Circle of Willis | 1 | 2009 | 3 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2005 | 1330 | 0.090 |
Why?
|
| Meningeal Arteries | 1 | 2009 | 9 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 396 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2001 | 481 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 492 | 0.080 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 28 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2009 | 89 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 742 | 0.080 |
Why?
|
| Middle Aged | 7 | 2011 | 21147 | 0.080 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 22 | 0.080 |
Why?
|
| Pyrroles | 1 | 2009 | 83 | 0.080 |
Why?
|
| Myography | 1 | 2008 | 4 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2008 | 24 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 150 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1515 | 0.080 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 71 | 0.080 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 35 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2008 | 136 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 384 | 0.080 |
Why?
|
| Angiography | 1 | 2008 | 194 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2022 | 330 | 0.070 |
Why?
|
| Collagenases | 1 | 2007 | 34 | 0.070 |
Why?
|
| Dinoprost | 1 | 2007 | 27 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 107 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 2223 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 1026 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2002 | 1553 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 214 | 0.070 |
Why?
|
| Arteries | 1 | 2007 | 108 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 23 | 0.070 |
Why?
|
| Colforsin | 1 | 2006 | 42 | 0.070 |
Why?
|
| Aged | 5 | 2011 | 14862 | 0.070 |
Why?
|
| Cell Compartmentation | 1 | 2006 | 41 | 0.070 |
Why?
|
| Elasticity | 1 | 2006 | 103 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 92 | 0.070 |
Why?
|
| Enzyme Activation | 3 | 2015 | 791 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2006 | 33 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 25 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 138 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2015 | 626 | 0.070 |
Why?
|
| Serotonin | 1 | 2006 | 144 | 0.070 |
Why?
|
| Gelatinases | 1 | 2005 | 12 | 0.070 |
Why?
|
| Diet | 1 | 2009 | 514 | 0.060 |
Why?
|
| Fibronectins | 1 | 2005 | 130 | 0.060 |
Why?
|
| Free Radicals | 1 | 2005 | 65 | 0.060 |
Why?
|
| Neutropenia | 1 | 2005 | 72 | 0.060 |
Why?
|
| Administration, Intravenous | 2 | 2017 | 89 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2004 | 31 | 0.060 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2004 | 11 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 579 | 0.060 |
Why?
|
| Angiopoietins | 1 | 2004 | 4 | 0.060 |
Why?
|
| Extracellular Matrix | 2 | 2006 | 493 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2005 | 77 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2004 | 4 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 320 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2006 | 525 | 0.060 |
Why?
|
| Swine | 3 | 2001 | 672 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2005 | 96 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 48 | 0.060 |
Why?
|
| Basigin | 1 | 2004 | 53 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2004 | 74 | 0.060 |
Why?
|
| Pterins | 1 | 2004 | 2 | 0.060 |
Why?
|
| Biopterin | 1 | 2004 | 10 | 0.060 |
Why?
|
| Biomarkers | 2 | 2007 | 1593 | 0.060 |
Why?
|
| Cyclic GMP | 2 | 2015 | 99 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 132 | 0.060 |
Why?
|
| Cyclic N-Oxides | 1 | 2003 | 17 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 337 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 126 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 57 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2005 | 174 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2004 | 230 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 191 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2003 | 48 | 0.060 |
Why?
|
| Cricetulus | 1 | 2003 | 98 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2004 | 220 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 567 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2003 | 234 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 105 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 163 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 244 | 0.050 |
Why?
|
| Plaque, Amyloid | 1 | 2022 | 31 | 0.050 |
Why?
|
| Protein Precursors | 1 | 2002 | 105 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2002 | 65 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2018 | 483 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 323 | 0.050 |
Why?
|
| Heart Arrest, Induced | 1 | 2001 | 52 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 782 | 0.050 |
Why?
|
| Iron | 1 | 2003 | 197 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 245 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2001 | 5 | 0.050 |
Why?
|
| Tetracyclines | 1 | 2000 | 3 | 0.050 |
Why?
|
| Memory, Long-Term | 1 | 2020 | 4 | 0.050 |
Why?
|
| Encephalitis | 2 | 2014 | 43 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2001 | 705 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1040 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2001 | 153 | 0.050 |
Why?
|
| Atrophy | 1 | 2020 | 112 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2001 | 223 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 951 | 0.050 |
Why?
|
| Sympathetic Nervous System | 1 | 2000 | 81 | 0.040 |
Why?
|
| Phenylephrine | 2 | 2010 | 61 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 2001 | 383 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 772 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 106 | 0.040 |
Why?
|
| Guanidines | 1 | 2019 | 32 | 0.040 |
Why?
|
| Rats, Inbred Dahl | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 167 | 0.040 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2000 | 174 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 770 | 0.040 |
Why?
|
| Carotid Arteries | 2 | 2013 | 110 | 0.040 |
Why?
|
| Pregnancy | 2 | 2015 | 2334 | 0.040 |
Why?
|
| Sensory Gating | 1 | 2018 | 4 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 147 | 0.040 |
Why?
|
| Epoetin Alfa | 1 | 2018 | 23 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 95 | 0.040 |
Why?
|
| Quinolones | 1 | 2019 | 60 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 266 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 4848 | 0.040 |
Why?
|
| Nogo Proteins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2000 | 328 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1753 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Receptor, trkB | 1 | 2017 | 27 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2017 | 32 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 242 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 70 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 99 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 195 | 0.030 |
Why?
|
| Prevalence | 1 | 2001 | 1619 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2000 | 738 | 0.030 |
Why?
|
| Angiotensins | 1 | 2016 | 16 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2016 | 50 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 23 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Purines | 1 | 2015 | 39 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2015 | 47 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1342 | 0.030 |
Why?
|
| Poetry as Topic | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hyperoxia | 1 | 2014 | 27 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 2014 | 27 | 0.030 |
Why?
|
| Geography | 1 | 2014 | 80 | 0.030 |
Why?
|
| Angiopoietin-1 | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 46 | 0.030 |
Why?
|
| Myelin Sheath | 1 | 2014 | 115 | 0.030 |
Why?
|
| Lactones | 1 | 2014 | 64 | 0.030 |
Why?
|
| Stilbenes | 1 | 2014 | 57 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 49 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 132 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 1615 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 71 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 284 | 0.030 |
Why?
|
| Research Personnel | 1 | 2014 | 83 | 0.030 |
Why?
|
| Animal Feed | 1 | 2013 | 52 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2013 | 54 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2014 | 110 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 5 | 0.030 |
Why?
|
| Rats, Zucker | 1 | 2013 | 10 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 119 | 0.030 |
Why?
|
| Adenylate Kinase | 1 | 2013 | 10 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2013 | 27 | 0.030 |
Why?
|
| TRPV Cation Channels | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2013 | 20 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 189 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 15 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 28 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 567 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2013 | 68 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 236 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 280 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 168 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 13 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 258 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 230 | 0.020 |
Why?
|
| Sexual Behavior, Animal | 1 | 2011 | 13 | 0.020 |
Why?
|
| Apomorphine | 1 | 2011 | 48 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 252 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2011 | 37 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 298 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 52 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2011 | 28 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 246 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 334 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 96 | 0.020 |
Why?
|
| Adult | 2 | 2006 | 21403 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 50 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 48 | 0.020 |
Why?
|
| Lung | 1 | 2015 | 849 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2015 | 902 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 247 | 0.020 |
Why?
|
| Estradiol | 1 | 2011 | 176 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 381 | 0.020 |
Why?
|
| RNA | 1 | 2010 | 171 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Glycosylation | 1 | 2009 | 185 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 260 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 867 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 62 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2008 | 26 | 0.020 |
Why?
|
| Microtubules | 1 | 2009 | 104 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2008 | 32 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 649 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 737 | 0.020 |
Why?
|
| United States | 1 | 2001 | 7367 | 0.020 |
Why?
|
| Flavonoids | 1 | 2008 | 109 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 238 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 117 | 0.020 |
Why?
|
| Hydralazine | 1 | 2007 | 12 | 0.020 |
Why?
|
| Telemetry | 1 | 2007 | 23 | 0.020 |
Why?
|
| Enalapril | 1 | 2007 | 86 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 238 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2279 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 218 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 331 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1864 | 0.020 |
Why?
|
| Cell Count | 1 | 2005 | 248 | 0.020 |
Why?
|
| Spin Labels | 1 | 2003 | 27 | 0.010 |
Why?
|
| Child | 1 | 2012 | 6405 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 164 | 0.010 |
Why?
|
| Microdialysis | 1 | 2000 | 147 | 0.010 |
Why?
|
| Linear Models | 1 | 2000 | 521 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 8912 | 0.000 |
Why?
|